For an adult with pancreatic cancer that has spread, the answer to “Can I receive daraxonrasib?” depends on where they live, what treatment they have already had and whether they can tolerate a combination of cancer medicines.

As of November 21, 2026, the United States and European Union have approved daraxonrasib, sold as Rasonque, for different groups of patients. In the UK, Pancreatic Cancer UK identifies clinical trials as the current route to the drug. The distinction matters particularly for someone about to start treatment for the first time.

United States: prior treatment or inability to receive a combination

The FDA approved Rasonque on August 26 for adults with metastatic pancreatic adenocarcinoma. The US indication includes people who have already received at least one systemic treatment, meaning a treatment that travels through the body. It also includes adults whose oncology team considers them unsuitable for treatment with several systemic drugs together.

The second group matters. An adult who has had no previous systemic therapy may fall within the US indication if multiagent treatment is unsuitable. A new diagnosis of metastatic disease, by itself, does not establish eligibility. The prescribing team can explain which part of the indication applies.

European Union: a single drug after earlier systemic therapy

The European Commission granted marketing authorisation on November 16. The approved use is daraxonrasib on its own for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The EU indication requires prior treatment even when a combination of drugs would be unsuitable.

The decision settles which use is authorised across the EU. The date on which a particular hospital can supply publicly funded treatment also depends on national pricing and reimbursement arrangements. For a patient who meets the EU indication, the next question for the oncology team is whether the local service can offer the drug and under what funding arrangements.

United Kingdom: ask about an open trial

The European Commission decision does not grant a UK licence. In its November update, Pancreatic Cancer UK said daraxonrasib was available only through clinical trials in the UK. Its trial finder lists studies, and an oncology team can check whether a study is recruiting at a reachable centre and whether its eligibility rules fit a patient’s treatment history.

UK licensing and NHS funding are separate decisions. In a June 15 parliamentary answer, the government explained the respective roles of the Medicines and Healthcare products Regulatory Agency in licensing and NICE in assessing NHS use. Neither the US approval date nor the EU decision sets an NHS access date.

What about taking daraxonrasib with chemotherapy?

The November results for daraxonrasib with chemotherapy concern a different question: whether adding the drug to gemcitabine and nab-paclitaxel benefits people starting treatment for metastatic disease. The US and EU decisions described above do not authorise that first-line combination.

For someone considering daraxonrasib now, the first practical question is which route applies to their circumstances: a prescription under the local approved indication, or screening for a clinical trial with its own entry criteria.